Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

NCT03799848 is registered in ClinicalTrials.gov with Akebia Therapeutics as lead sponsor.

NCT NCT03799848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03799848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
Lead sponsor
Akebia Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
June 12, 2018
Completion date
October 18, 2018
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment